University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Outperforming many analysts’ expectations, French drugmaker Sanofi has posted revenues of 10.2 billion euros ($11.3 billion) for the first quarter 2023. 27 April 2023
The US Food and |Drug Administration (FDA) has released briefing documents for the April 28, 2023, Advisory Committee Meeting (AdCom) discussing the supplemental new drug application (sNDA) for UK AstraZeneca’s Lynparza (olaparib) in first-line (1L) metastatic castration-resistant prostate cancer (mCRPC). 27 April 2023
Kidney disease specialist Akebia Therapeutics saw its shares lifted over 6% on Monday, following a European approval for Vafseo (vadadustat). 26 April 2023
Swiss pharma giant Roche says that, in the first three months of 2023, group sales declined by 3% (-7% in Swiss franc term) to 15.3 billion francs ($17.2 billion). 26 April 2023
German family-owned drugmaker Grünenthal says it has successfully placed its 300 million-euro ($329 million) aggregate principal amount of 6.75% senior secured notes due 2030. 26 April 2023
Swiss pharma giant Novartis was trading 3% higher on Tuesday afternoon after presenting its first-quarter 2023 financial results and latest full-year guidance. 25 April 2023
Californian specialty drugmaker Amphastar Pharmaceuticals has bought Baqsimi (glucagon) from Eli Lilly, in a deal worth over a billion dollars. 25 April 2023
UK-based drugmaker Advanz Pharma has bought global rights to the testosterone gel Tostran (testosterone) from Japanese biotech Kyowa Kirin. 25 April 2023
Navigating the ever-increasing challenges of antimicrobial resistance (AMR), which occurs when bacteria, viruses, fungi, or parasites no longer respond to antimicrobial treatment, has been a key theme at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2023 conference. 25 April 2023
The European Medicines Agency has provided Johnson & Johnson with its first regulatory approval for Akeega (niraparib/abiraterone acetate). 24 April 2023
The European Medicines Agency (EMA) has opened a public consultation on a reflection paper that discusses key concepts for single-arm clinical trials submitted as pivotal evidence in support of marketing authorization applications. 21 April 2023
Japanese pharmaceutical giant Takeda is considering selling its Russian plant that produces, Ninlaro (ixazomib), a treatment for patients with multiple myeloma as well as other drugs, according to some local market analysts and Russian media, The Pharma Letters local correspondent reports. 21 April 2023
The Russia government has updated the existing draft strategy for the development of the domestic pharmaceutical industry - Pharma-2030, reports The Pharma Letter’s local correspondent. 20 April 2023
The world’s top 20 biopharma companies reported a drop in their combined market capitalization by 3.4% from $3.61 trillion at the end of 2022, to $3.49 trillion after the first three months of 2023. 20 April 2023
Pharma major GSK has been caught up in a wave of industrial action hitting British companies, as the UK struggles with stubbornly high inflation and a rising cost of living. 19 April 2023